Curis Lifesciences IPO Analysis

As Curis Lifesciences hits the SME IPO market, investors are weighing its science-led edge against modest scale and operational depth — a test of whether innovation can convert to investor conviction.

Here’s what Curis Lifesciences is bringing to the table:

Industry Overview

India’s pharmaceutical industry stands as the third-largest globally by volume and fourteenth by value, built on its strength in generics and branded generics, which account for nearly 70% of the market. The rest is driven by APIs (~20%) and contract manufacturing (~10%), segments that typically operate within 14–22% margin ranges.

Curis Lifesciences sits within this formulation in the contract manufacturing segment—a cost-competitive, low-IP segment where scale and efficiency outweigh innovation.

Overall, the Indian pharma sector contributes about 1.7% to GDP, with a market size of ~$50 billion, expected to more than double to $120–130 billion by 2030, powered by government incentives, export growth, and a maturing R&D base.

The company currently holds 943 product approvals under two manufacturing licenses. Its current portfolio largely covers antibiotics, antifungals, analgesics, and gastrointestinal medicines which are broad but basic generic categories. It lacks exposure to high-barrier, complex segments such as oncology, hormones, injectables, and high-potency APIs, which typically drive better margins and sustainable differentiation.

Business Model

Curis Lifesciences operates a multi-vertical pharmaceutical manufacturing model serving both domestic and international markets. Its business is structured across three key verticals:

• Loan Licence Manufacturing: The clients provide the necessary raw materials, guidance, supporting documents and formulations, following which they make their products. Low margin segment due to fixed fee per batch — the client captures the upside margin.

• Contract Manufacturing: The company procures its own raw materials, manufactures finished products, and supplies them to clients who market these under their own brands. Higher margins through merchant exports but lower pricing power.

• Direct Export/Own Brand Manufacturing: Alongside its B2B focus, Curis has also begun building an export-led branded business by marketing its own formulations in select overseas markets such as Yemen and Kenya. High margin segment in semi-regulated markets.

A company like Curis, working in this pharmaceutical segment, can earn profits and achieve growth through either increasing its product diversification or moving towards economies of scale through expansion. 

Curis Lifesciences’ topline is largely driven by contract manufacturing through merchant exporters, accounting for over half its revenue. Domestic operations contribute around 97–99% of total revenue, while direct exports remain below 1%, though a portion of domestic sales is routed through merchant exporters serving foreign markets.

Despite having over 900 approved formulations, nearly 70% of output comes from basic oral tablets and capsules, underscoring a lack of diversification into complex generics or specialty therapies. The company primarily competes on cost efficiency, not product innovation, creating a limiting factor for long-term margin expansion.

Peers like Sotac Pharmaceuticals and Lincoln Pharmaceuticals have diversified into specialized therapeutic areas, enabling better pricing power and higher-margin product mixes — a strategic gap Curis is yet to cross.

Manufacturing and Utilization

The company operates from a single WHO-GMP certified facility in Sanand, Gujarat, equipped for multiple dosage forms. However, overall utilization remains below 50%, well under the industry benchmark of 70–75%.

The low utilization levels indicate underleveraged assets and limited economies of scale. The IPO proceeds aim to upgrade machinery and expand storage facilities, expected to lift utilization by 5–10%, though still below industry norms.

Customer Count

Despite a three-year rise in customer count from 46 in FY23 to 61 by July 2025, Curis Lifesciences’ client growth appears slowed down. Most of the addition came from domestic suppliers, while merchant exporter clients have barely increased. The overall expansion indicates limited new customer acquisition and reliance on existing relationships, highlighting slow business development momentum.

Curis has begun product registrations in Kenya and the Democratic Republic of Congo (DRC) using IPO proceeds, aiming to widen its export markets. However, the absence of USFDA or EU-GMP accreditation limits access to high-value regulated markets—these markets have lower regulations on prices. Its current export strategy is focused on semi-regulated geographies, where entry barriers are lower but so are margins.

Peer Company Valuation

At the upper price band, Curis Lifesciences is valued at around 12x FY25 earnings, broadly in line with SME pharma peers. Peers such as Sotac have already advanced into regulated dossier markets, enabling higher-margin CDMO contracts, while Curis remains primarily a domestic CMO — limiting its long-term scalability.

The company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

• Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities

• Capital Expenditure towards Construction of a Storage Facility 

• Pre-payment/Repayment of outstanding Secured Loans

• Product Registrations in other countries

• Funding our Working Capital Requirements

• General Corporate Purpose

The issue is growth-supportive, not expansionary — indicating operational fine-tuning rather than capacity addition.

Financial Performance

Curis Lifesciences has demonstrated a steady growth trajectory with revenue rising from ₹35.4 crore in FY23 to ₹49.1 crore in FY25.

EBITDA margin spiked from 9% to 23% in FY24 before settling back to 19% in FY25. This fluctuation indicates limited pricing power and dependence on specific high-margin batches or orders.

PAT margin improvement from 5.3% to 12.4% is positive, but largely reflective of cost optimization and lower interest burden, not necessarily topline quality or product differentiation.

The company’s debt-equity ratio fell from a worrying 16x in FY23 to under 1x in FY25 after significant equity infusion and debt repayment signaling strength in the balance sheet. 

Strengths:

• WHO-GMP certified facility with capacity across tablets, capsules, liquids, ointments, and sterile formulations.

• Reduced debt in the company by bringing down D/E from 16x to 0.8x recently.

• Expansion through capex expansion and product registrations in more countries with the upcoming IPO.

• No direct marketing or R&D burden; focuses purely on manufacturing efficiency.

• Large installed capacity with scope to double output once utilization improves.

Risks:

• Top 5 customers contribute >90% of revenue; dependency risk high.

• Current utilization below 50% — idle assets dilute operating leverage.

• Focus on low-differentiation generics limits pricing power and margins.

• Absence of USFDA/EU-GMP certifications restricts access to high-value regulated markets.

• Sustained negative cash flows in key areas could hinder growth and financial stability.

• Execution risk around successful product registrations and export expansion.
  
  

Final Words

At Alpha Venture X Fund, every opportunity is evaluated through our proprietary LMVT framework — Leadership, Moat, Valuation, and Tailwinds, designed to identify scalable, high-quality businesses.

Through this lens, Curis Lifesciences emerges as a stable yet limited-growth pharma manufacturer. While the Leadership team demonstrates operational discipline, the company lacks a durable Moat — operating in a fragmented, low-margin CMO space with minimal exposure to regulated markets or complex formulations.

From a Valuation standpoint, the issue appears reasonable, but growth visibility and margin sustainability remain modest given client dependence and low export penetration. On Tailwinds, despite a favorable sector backdrop, Curis’ positioning restricts its ability to capture the broader upcycle.

Overall, Curis aligns with operational steadiness, not scalable differentiation, and thus does not fit our investment mandate at this stage.